Cedar Brook Financial Partners’s Abeona Therapeutics ABEO Stock Holding History

Cedar Brook Financial Partners’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,200	Closed	-$11K	–	350
2022 Q2	$11K	Hold	2,200	–	–	﹤0.01%	345
2022 Q1	$17K	Hold	2,200	–	–	﹤0.01%	377
2021 Q4	$19K	Hold	2,200	–	–	﹤0.01%	380
2021 Q3	$62K	Hold	2,200	–	–	0.02%	344
2021 Q2	$86K	Hold	2,200	–	–	0.02%	367
2021 Q1	$103K	Hold	2,200	–	–	0.04%	315
2020 Q4	$86K	Hold	2,200	–	–	0.03%	318
2020 Q3	$56K	Hold	2,200	–	–	0.02%	289
2020 Q2	$160K	Hold	2,200	–	–	0.07%	266
2020 Q1	$116K	Hold	2,200	–	–	0.06%	238
2019 Q4	$180K	Hold	2,200	–	–	0.08%	279
2019 Q3	$124K	Hold	2,200	–	–	0.05%	293
2019 Q2	$263K	Hold	2,200	–	–	0.12%	227
2019 Q1	$405K	Hold	2,200	–	–	0.2%	160
2018 Q4	$393K	Buy	+2,200	New	+$480K	0.24%	141

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cedar Brook Financial Partners's ABEO Position: Q3 2022 in Review

Cedar Brook Financial Partners sold out of Abeona Therapeutics (ABEO) in Q3 2022, closing a stake of 2,200 shares — an estimated $11K sold.

Cedar Brook Financial Partners first reported a position in ABEO in Q4 2018 and held it in 15 quarters. The position peaked at $405K in Q1 2019. 24 funds tracked by Wall St. Rank hold ABEO as of Q3 2022.

Cedar Brook Financial Partners reported no remaining Abeona Therapeutics position as of Q3 2022 after selling out during the quarter.
Cedar Brook Financial Partners sold 2,200 Abeona Therapeutics shares in Q3 2022, an estimated $11K.
Cedar Brook Financial Partners first reported a position in Abeona Therapeutics in Q4 2018 and held it in 15 quarters.
Cedar Brook Financial Partners's Abeona Therapeutics position peaked at $405K in Q1 2019.
24 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2022.

Based on Cedar Brook Financial Partners's 13F filing for Q3 2022, filed 3 Jan 2023.